• Since non lipoprotein derived free cholesterol is

  2025-01-17

  

  Since non-lipoprotein-derived free cholesterol is recycled from the plasma membrane through the endosomal system through receptor-independent mechanisms, we wanted to determine whether ABCA2 could alter the trafficking of this source of free cholesterol. Our approach was to measure the effect of mob

• In eukaryotes class III ACs

  2025-01-17

  

  In eukaryotes, class III ACs (including GCs) are almost universally present, with the noteworthy exception of higher plants. Our dataset comprises 9690 sequences of class III nucleotide cyclases from 710 eukaryotic species. Approximately 80% thereof belong to subclass IIIa and 10% to subclasses IIIb

• Cofilin is an additional actin severing protein present in s

  2025-01-17

  

  Cofilin is an additional Taxifolin synthesis severing protein present in sperm cells that undergo phosphorylation/inactivation on serine 3 by Lim kinases (LIMK) and by Tes kinases (TESK) [48]. LIMK can be activated by several pathways, including one through the Rho/ROCK/LIMK cascade [49], [50], [51]

• br Conflicts of interest br Acknowledgments br

  2025-01-17

  

  Conflicts of interest Acknowledgments Significance Introduction Androgen receptor (AR) plays a paramount role in the onset and progression of prostate cancer (PC) (Burnstein, 2005, Lonergan and Tindall, 2011, Watson et al., 2015). This very facet underlies androgen deprivation therapy (A

• br Funding br Introduction l Dihydroxyphenylalanine l DOPA i

  2025-01-17

  

  Funding Introduction l-3,4-Dihydroxyphenylalanine (l-DOPA) is the gold-standard treatment for the motor symptoms of Parkinson's disease (PD); however, its chronic use induces severe motor complications that eventually limit its long-term efficacy (Bastide et al., 2015). The most disabling side

• Additional evidence for a putative

  2025-01-17

  

  Additional evidence for a putative role of COXs and 5-LOX in AD derives from pharmacological studies using inhibitors of these enzymes (for review, see Firuzi and Praticò, 2006). In addition to helping delineate the pathobiological mechanisms of AD, these results raise hope for discovering novel the

• To test the compounds metabolic

  2025-01-17

  

  To test the compounds metabolic stability, we measured the half-life of compounds and in mouse hepatic microsomes (1mg/mL) and found them to have modest stability, with half-lives of 7.5 and 2.9min respectively, indicating these compounds may be unsuitable for studies. In order to gain structura

• To evaluate the ability of both sets of compounds to

  2025-01-17

  

  To evaluate the ability of both sets of compounds to inhibit the activity of 15-LOX an initial screen was performed, whose results are shown in . The comparison of inhibition values would seem to indicate that, in the HYD series, an electron donor group at the position increases and an electron att

• At Johns Hopkins Aramco Health JHAH we started an ASP

  2025-01-16

  

  At Johns Hopkins Aramco Health (JHAH), we started an ASP in 2011 with an educational program of physicians and pharmacist. The program was enhanced mid-2012 with the following interventions: a re-designed antibiotic sensitivity report [2], intravenous to oral conversion program, vancomycin pharmacok

• Oncogenic Ras blocker Several studies have explored the

  2025-01-16

  

  Several studies have explored the relationship between dental implants and MRONJ development. López-Cedrún JL et al. [13] reported that BRONJ developed after implant treatment in nine patients who were taking bisphosphonates orally. The mean interval between the initiation of treatment and the onset

• br Antiangiogenic therapy in non small cell

  2025-01-16

  

  Antiangiogenic therapy in non-small cell lung cancer (NSCLC) Antiangiogenic targeted therapy is an area of active research in which numerous agents have been studied and have been shown to be effective for many tumor types including NSCLC. Angiogenesis is frequently upregulated in malignant solid

• We provide here direct evidences that AT receptors are

  2025-01-16

  

  We provide here direct evidences that AT1 receptors are active in ADSCs since Ang II induces intracellular Ca mobilization in these cells. Data obtained during the observation of Ca influxes led us to the search for the ADSCs subpopulation constantly expressing AT1 receptor. ADSCs are necessary for

• br Under normal physiological conditions the

  2025-01-16

  

  Under normal physiological conditions, the agonist binds to AT1R on the surface of the plasma membrane and activates the receptor, mediating downstream signaling. Then, activated AT1R is phosphorylated by protein kinase C (PKC) [13] or G protein coupled receptor kinases (GPKs, such as GRK2 [13], G

• Acute myeloid leukemia treatment Furthermore a recently publ

  2025-01-16

  

  Furthermore, a recently published network meta-analysis including 30 trials in patients with hypertension and diabetes demonstrated that ARBs have efficacy similar to that of ACEIs for all-cause and cardiovascular mortality (HR 0.95, 95% CI 0.73 to 1.30 and HR 1.23, 95% CI 0.64 to 2.78, respectively

• The RE compartment has been shown to be

  2025-01-16

  

  The RE compartment has been shown to be critical for supplying AMPAR during LTP (Hanley, 2010; Park et al., 2004), but whether they also supply AMPAR for synaptic scaling has been less clear (Gainey et al., 2015; Tan et al., 2015). Interestingly, although an increase in μ3A is necessary for scaling,

14567 records 35/972 page Previous Next First page 上5页 3132333435 下5页 Last page